Kringle Pharma, Inc. 4884

TSE · Japan · Health Technology

¥484.00-13.00 (-2.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Kringle Pharma, Inc. 4884

TSE · Japan · Health Technology

¥484.00-13.00 (-2.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-5.84% · 6MFull-screen chart

Open ¥492.00High ¥497.00Low ¥479.00Close ¥484.00Volume 83.00K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: ¥497.00
Day range: ¥479.00 – ¥497.00
52-week range: ¥287.00 – ¥601.00
Volume: 83.00K
Market cap: ¥4.27B
Next earnings date: 2026-11-16
Avg. volume (1Y): 308.77K

Performance

1 week

-4.54%

1 month

+10.25%

3 months

+44.05%

6 months

+8.04%

Year to date

+23.47%

1 year

+10.50%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Japan
Exchange: TSE
Shares outstanding: 8.59M
Employees: 17
ISIN: JP3270790003
Beta: 0.54

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 02, 2026

The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight

The SCI treatment pipeline continues to expand, featuring candidates such as KP-100IT (Kringle Pharma), Neuro-Cells (Neuroplast), MT-3921 (Mitsubishi Tanabe Pharma America), Elezanumab (AbbVie), PMZ-1620 (Pharmazz), NFX88 (Neurofix), NVG-291 (NervGen Pharma), and others. The introduction of these innovative spinal cord injury therapies is expected to revolutionize the SCI treatment landscape in the coming years.New York, USA, April 02, 2026 (GLOBE NEWSWIRE) -- The Rise of 6 Emerging Therapies in

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.